Media coverage about Akers Biosciences (NASDAQ:AKER) has trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Akers Biosciences earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned media coverage about the medical instruments supplier an impact score of 48.4032669195813 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Akers Biosciences traded up $0.07, reaching $0.51, during trading on Tuesday, according to Marketbeat.com. The company had a trading volume of 12,130 shares, compared to its average volume of 14,400,063. Akers Biosciences has a 12-month low of $0.45 and a 12-month high of $0.51.
Get Akers Biosciences alerts:
Akers Biosciences (NASDAQ:AKER) last released its earnings results on Tuesday, April 3rd. The medical instruments supplier reported ($0.23) EPS for the quarter. Akers Biosciences had a negative return on equity of 104.85% and a negative net margin of 147.74%. The company had revenue of $1.39 million during the quarter.
About Akers Biosciences
Akers Biosciences, Inc, together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness.